tarsus-logo-stacked-color-532x626.png
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
24 juil. 2021 18h00 HE | Tarsus Pharmaceuticals, Inc
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette...
eyenuk_logo_redesign_2017_onecolor.png
Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy
20 juil. 2021 08h00 HE | Eyenuk, Inc.
LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
22157.jpg
Dry Eye Disease Clinical Landscape Report 2021: Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie
08 juil. 2021 07h08 HE | Research and Markets
Dublin, July 08, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Dry Eye Disease" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Systemic Lupus...
tarsus-logo-stacked-color-532x626.png
Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
07 juil. 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Nextech-Logo-JPG.jpg
Midwest Vision Partners Selects Nextech’s IntelleChartPRO
06 juil. 2021 13h30 HE | Nextech Systems, Inc.
TAMPA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Nextech Systems, a leading provider of healthcare technology solutions for specialty providers, today announced a new partnership with Midwest Vision...
tarsus-logo-stacked-color-532x626.png
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
18 juin 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
22157.jpg
Global Thyroid Eye Disease (TED) Market Report 2021: Horizon Therapeutics has the Highest Amount of Ongoing Clinical Trials and Highest Overall Number of Clinical Trials
18 juin 2021 05h38 HE | Research and Markets
Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Thyroid Eye Disease (TED)" report has been added to ResearchAndMarkets.com's offering. Thyroid eye disease (TED), also called Graves'...
22157.jpg
Global Glaucoma Market Pipeline Spotlight Report 2021 - Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie
10 juin 2021 06h43 HE | Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Glaucoma" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Glaucoma market,...
logo color s and clearside.jpg
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
09 juin 2021 07h05 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
NOVARTIS logo.jpg
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
28 mai 2021 16h30 HE | Novartis Pharma AG
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus...